Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MAZE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMaze Therapeutics prices $144.7M equity offering to fund drug development through 2029
Filed April 22, 2026 · Period ending April 21, 2026 · ~1 min read
Key Changes
-
high
Company sold 5.54M shares at $23.50 and 850K pre-funded warrants at $23.499, netting $144.7M after fees—immediate dilution of roughly 6.4M shares to existing holders.
Item 1.01 view on EDGAR → -
high
Proceeds will primarily fund R&D for two drug candidates: MZE829 for kidney disease and MZE782 for PKU and chronic kidney disease, plus general corporate use.
Item 1.01 view on EDGAR → -
high
Combined with existing cash, the offering extends operational runway into 2029, eliminating near-term financing risk for approximately $23.50 three years.
Item 1.01 view on EDGAR → -
medium
Pre-funded warrants are immediately exercisable at $0.001 per share with ownership caps (4.99%-19.99%) to prevent concentration; economically equivalent to common stock.
Item 1.01 view on EDGAR →
Summary
Maze Therapeutics completed a $144.7 million equity raise on April 21, 2026, selling 5.54 million common shares at $23.50 each and 850,000 pre-funded warrants priced at $23.499. The pre-funded warrants carry a nominal $0.001 exercise price and are immediately exercisable, making them functionally identical to common stock. Existing shareholders face approximately 6.4 million shares of dilution from this offering.
The capital will primarily advance two clinical programs: MZE829 for APOL1-mediated kidney disease and MZE782 for phenylketonuria and chronic kidney disease.
Management projects the proceeds, combined with current cash reserves, will fund operations into 2029—a roughly three-year runway that removes near-term financing uncertainty and allows the company to focus on clinical execution without additional dilutive events in the immediate future. Retail investors should monitor clinical trial readouts for MZE829 and MZE782 over the next 12-18 months. Positive data would validate the capital deployment; setbacks could pressure the stock and potentially require the company to revisit its capital strategy before 2029.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 21, 2026, Maze Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC as sole underwriter (the “Underwriter”), pursuant to which the Company agreed to issue and sell an aggregate of (a) 5,540,000 shares of its common stock (the “Shares”) and (b) pre-funded warrants to purchase 850,000 shares of its common stock (the “Pre-Funded Warrants”) to the Underwriter (the “Offering”). The Shares will be sold at the offering price of $23.50 per Share. The Pre-Funded Warrants will be sold at an offering price of $23.499 per Pre-Funded Warrant, which represents the per share offering price for the Shares less a $0.001 per share exercise price for each such Pre-Funded Warrant.
The company priced a public offering of 5.54 million common shares at $23.50 each and 850,000 pre-funded warrants at $23.499 each (effectively $23.50 minus a $0.001 exercise price). This represents immediate equity dilution for existing shareholders through the issuance of new shares.
Added in current filing · verify on EDGAR →
The Company estimates that net proceeds from the Offering will be approximately $144.7 million, after deducting underwriting discounts and commissions and estimated offering expenses. ... The Company currently intends to use any net proceeds from the Offering primarily to advance research and development of the Company’s product candidates, including MZE829 for the treatment of APOL1-mediated kidney disease (“AMKD”) and MZE782 for the treatment of phenylketonuria (“PKU”) and chronic kidney disease (“CKD”), as well as for general corporate purposes.
The company expects to net approximately $144.7 million after fees and will use the proceeds primarily to advance R&D for two drug candidates: MZE829 for kidney disease and MZE782 for PKU and CKD, plus general corporate purposes. This provides clarity on how the dilutive capital will be deployed.
Added in current filing · verify on EDGAR →
The Company expects that the net proceeds from the Offering, together with its current cash, cash equivalents and marketable securities, will fund operations into 2029 based on its current business plan.
Management projects the offering proceeds combined with existing cash will extend the company's operational runway into 2029. This indicates the company has secured sufficient capital to fund operations for approximately $23.50 three years without needing additional financing, reducing near-term dilution risk.
Added in current filing · verify on EDGAR →
The Pre-Funded Warrants are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% or 9.99%, at the election of the holder, of the number of shares of common stock outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage, but not in excess of 19.99%, by providing at least 61 days’ prior notice to the Company.
The pre-funded warrants are immediately exercisable but include ownership caps (4.99% or 9.99% at holder's election, adjustable up to 19.99% with notice) to prevent any single holder from accumulating excessive ownership through exercise. These warrants represent potential additional dilution of 850,000 shares, though the nominal $0.001 exercise price means they are economically equivalent to common shares.
Event · Item 9.01 — Financial Statements and Exhibits
Maze Therapeutics disclosed an underwritten public offering with pre-funded warrants priced on April 21, 2026.
Added in current filing · verify on EDGAR →
Underwriting Agreement by and between Maze Therapeutics, Inc. and Leerink Partners LLC, dated April 21, 2026.
The company entered into an underwriting agreement with Leerink Partners LLC on April 21, 2026, indicating a public offering of securities. The filing includes a press release announcing the pricing of the offering and a form of pre-funded warrant, suggesting the company is raising capital through a combination of common stock and/or pre-funded warrants.
Added in current filing · verify on EDGAR →
Form of Pre-Funded Warrant.
The company is issuing pre-funded warrants as part of the offering. Pre-funded warrants allow investors to purchase shares at a nominal exercise price and are often used as an alternative to direct common stock issuance in registered offerings.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify